Welcome to our dedicated page for Blueberries Medi news (Ticker: BBRRF), a resource for investors and traders seeking the latest updates and insights on Blueberries Medi stock.
Blueberries Medical Co (BBRRF) delivers pharmaceutical-grade medical cannabis solutions across Latin America through advanced cultivation and patient-focused research. This news hub provides investors and healthcare professionals with essential updates about the company's operational milestones and therapeutic innovations.
Access timely reports on earnings announcements, regulatory compliance developments, and research breakthroughs alongside details about strategic partnerships and product line expansions. Our curated news collection enables stakeholders to track both financial performance and medical impact.
Bookmark this page for verified updates about production facility upgrades, international market entries, and clinical trial progress. All content undergoes strict verification to ensure alignment with medical cannabis industry standards and financial reporting requirements.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) reported a 110% increase in revenue for the year ended December 31, 2021, totaling $138,747. The company faced challenges due to market conditions and regulatory impacts but anticipates growth following the approval of Decree 811 allowing exports of dried cannabis from Colombia. Despite an increase in revenues, the company incurred a substantial net loss of $5,147,012 and recognized significant impairments on assets totaling $3,388,518. The management is focused on cash management and establishing processing capabilities to drive future sales growth.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) reported significant financial growth for the nine months ended September 30, 2021. Revenue surged by 339% to $173,886, up from $39,607 in the same period last year. Gross margin increased to 63%, while the company successfully reduced operating expenses by 55%, amounting to around $1,932,072. Notable achievements include the export of 150kg of CBD oil to Peru, marking its largest sale to date, and securing regulatory approval for new agricultural operations in Colombia. The company's cash position improved substantially following a private placement of $1.9 million.
Blueberries Medical Corp. (OTC: BBRRF) announced that its subsidiary in Colombia secured registration as a plant breeding unit and seed exporter. This authorization from the Colombian Agricultural Institute allows the company to enhance research on new cultivars, improving yield, cannabinoid profiles, and agronomic management. Additionally, the ability to export seeds opens up emerging market opportunities in Latin America. Executives highlighted the potential for income generation and international sales expansion, particularly in Argentina and Uruguay.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) announced a significant milestone with its subsidiary Blueberries SAS exporting 150 kg of premium CBD oil to Futura Farms Peru. This transaction marks the largest sale since its inception in 2018, benefiting approximately 2,500 patients in Peru. The company aims to enhance its revenue generation, expecting over 700% growth compared to the previous fiscal year, supported by a recent USD 1.5M capital injection for operations and expansion.
Blueberries Medical Corp. (CSE: BBM, OTC: BBRRF) announces its Annual General Meeting (AGM) scheduled for Wednesday, September 29, 2021, at 1:00 PM Eastern Time. Due to COVID-19 restrictions, the meeting will be held online, and in-person attendance will require proof of vaccination. Shareholders are encouraged to vote by proxy ahead of the meeting. The AGM will include a management update and presentation following formal proceedings. The deadline for proxy voting is September 27, 2021, at 1:00 PM Eastern Time.
Blueberries Medical Corp. (CSE: BBM, OTC: BBRRF) has completed a non-brokered private placement, raising C$1,901,382 (approximately US$1.5 million) by issuing 20,813,817 common shares at C$0.10 each. The proceeds will be utilized for marketing strategies, equipment improvements, and certifications. Terraflos Inc. led the offering and recently closed an US$8 million funding round to expand its operations in Latin America. Additionally, Joaquín Barbera has been appointed as a new independent director, bringing expertise in innovation and sustainability to the board.
Blueberries Medical Corp. (CSE: BBM, OTC: BBRRF) reported financial results for Q2 2021, showing revenue growth to $14,785 from $4,644 in Q2 2020. The company reduced Selling General & Administrative Expenses significantly from $411,132 in H1 2020 to $209,114 in H1 2021. Despite these gains, Blueberries incurred a net loss of $269,067 in Q2 2021, a decrease from $814,084 in Q2 2020. The company is aligning strategies to minimize costs while expanding revenue through new services and partnerships in Colombia and Uruguay.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) reported financial results for Q1 2021, highlighting revenues of $23,120 compared to $0 in Q1 2020. The gross profit stood at $21,925, while net loss narrowed to $590,325 from $1,669,354 in the previous year. The company appointed Guillermo P. Rodriguez as CFO effective June 1, 2021. Blueberries continues to develop its cannabis operations, launching sales to Peru and preparing for domestic production in Colombia. Key achievements include a certification from LABFARVE for cannabis formulations.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) has reported its 2020 financial results, indicating revenues of $65,978 from commercial cannabis operations after commencing sales in late Q2 2020. Despite significant cost-saving measures, the net loss narrowed to $4,940,107 from $10,787,876 in 2019. The company has focused on cash management, processing capabilities, and establishing sales growth amidst COVID-19 disruptions. Total assets decreased to $7,270,212 while total liabilities rose to $3,380,433.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) has announced a strategic agreement with Futura Farms to supply 200 kg of premium cannabis oil to Peru, marking its first entry into this market. Peru's medical cannabis market is projected to be worth US$99 million, and this partnership aligns with Blueberries' growth strategy across Latin America, including Colombia and the USA. The agreement is intended to cater to licensed pharmaceutical establishments compliant with Peru's Good Storage Practices. Both companies aim to enhance the quality of medical cannabis treatments in the region.
